An event of atrial fibrillation was reported.A returned device assessment could not be performed as the device was not returned for analysis.The device history record was reviewed to ensure that each manufacturing and inspection operation was performed and the product met all specifications.Based on the information received, the cause of the reported incident could not be conclusively determined.There is no indication of a product quality issue with regards to manufacture, design, or labeling.
|
Clinical information: (b)(6), patient site id: (b)(6).It was reported that on (b)(6) 2024, a 25-18mm amplatzer talisman pfo occluder was chosen for procedure using a 10f amplatzer trevisio intravascular delivery system.During procedure, the activated clotting levels were 277 seconds, and 9000 units of heparin was administered.The device was implanted successfully.There was no delay in the procedure.One minute after the deployment, an atrial fibrillation was noted with rapid ventricular response.Amiodarone was given via intravenous and patient was converted back to normal sinus rhythm.The patient was reported discharged in stable condition.
|